Taurus Armas board signs off on Q2 2026 consolidated financial statements (ITR)
Reuters2026/08/11 23:42- Taurus Armas’ board cleared the company’s 2Q26 consolidated quarterly financial statements in a meeting resumed on Aug. 11.
- Directors endorsed the ITR filing for 2Q26, reflecting the quarter’s operating performance and consolidated accounting information.
- The package included favorable opinions from the Audit and Risk Committee, supported by the Fiscal Council.
- The meeting opened on Aug. 6, then paused without a decision before concluding with a unanimous vote.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.
Electra Therapeutics Inc. has officially filed for an initial public offering (IPO), aiming to leverage the strong IPO performance of the biotechnology sector this year to raise funds for its clinical-stage pipeline of drugs targeting immune-mediated diseases and cancer.
Fogo Foundation Attacked, Approximately 400 Million FOGO Tokens Transferred
Blue Owl (OWL.US) teams up with PIMCO to tailor a $2.4 billion GPU financing for IREN (IREN.US)
A $2.4 billions debt financing round, led by funds under Blue Owl Capital Inc., has been finalized. The funds will be allocated to cloud service provider IREN Ltd. to purchase NVIDIA's Blackwell Ultra GPUs, supporting the development of its data center campus in Canada.
Crypto prices
More
